A Trial of TTI-621 in Combination With Doxorubicin in Patients With Leiomyosarcoma
Status:
Recruiting
Trial end date:
2024-07-31
Target enrollment:
Participant gender:
Summary
Multi-center, open-label, Phase I/II dose escalation and expansion trial of TTI-621 in
patients with unresectable or metastatic high-grade leiomyosarcoma.